middle.news
Acrux gains FDA clarity for female testosterone Phase III
9:30am on Monday 12th of October, 2026 AEDT
•
Healthcare
Read Story
Acrux gains FDA clarity for female testosterone Phase III
9:30am on Monday 12th of October, 2026 AEDT
Key Points
Two 24-week Phase III efficacy trials required
52 weeks of data to support chronic safety
Potential three-year FDA data exclusivity
Acrux finalising trial and safety-study protocols
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Acrux (ASX:ACR)
OPEN ARTICLE